Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...

Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood ...

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

Lynozyfic (linvoseltamab) has been given accelerated approval by the US regulator for adults with relapsed or refractory ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron ...

FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial.

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

The US Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals’ Lynozyfic ...

Regeneron is hoping a new program will widen patient access to its eye drug without also benefiting the company's rivals — a ...

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for ...

The FDA is investigating two deaths in non-ambulatory Duchenne muscular dystrophy patients who received a Sarepta gene ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals. If we consider the specifics of each trade, it is accurate to state that 50% of the investors ...